A detailed history of Advisor Group Holdings, Inc. transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 657 shares of CRBU stock, worth $1,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares
657
Previous 1,177 44.18%
Holding current value
$1,182
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.56 - $2.73 $811 - $1,419
-520 Reduced 44.18%
657 $1,000
Q2 2024

Aug 13, 2024

SELL
$1.62 - $5.05 $1,020 - $3,181
-630 Reduced 34.86%
1,177 $1,000
Q1 2024

May 10, 2024

SELL
$4.82 - $8.26 $1,788 - $3,064
-371 Reduced 17.03%
1,807 $9,000
Q4 2023

Feb 12, 2024

SELL
$3.58 - $6.25 $28,310 - $49,425
-7,908 Reduced 78.41%
2,178 $12,000
Q3 2023

Nov 13, 2023

BUY
$4.08 - $8.14 $24,626 - $49,133
6,036 Added 149.04%
10,086 $48,000
Q2 2023

Aug 10, 2023

BUY
$4.04 - $5.47 $909 - $1,230
225 Added 5.88%
4,050 $17,000
Q1 2023

May 12, 2023

SELL
$4.3 - $7.78 $477 - $863
-111 Reduced 2.82%
3,825 $20,000
Q4 2022

Feb 10, 2023

SELL
$5.57 - $11.01 $300 - $594
-54 Reduced 1.35%
3,936 $24,000
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $13,985 - $33,497
2,619 Added 191.03%
3,990 $42,000
Q2 2022

Aug 10, 2022

BUY
$5.1 - $9.74 $2,947 - $5,629
578 Added 72.89%
1,371 $7,000
Q1 2022

May 04, 2022

SELL
$8.42 - $15.32 $707 - $1,286
-84 Reduced 9.58%
793 $7,000
Q3 2021

Nov 05, 2021

BUY
$15.75 - $30.29 $13,812 - $26,564
877 New
877 $21,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.